Odyssey Therapeutics, Inc. (ODTX)
Odyssey Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Odyssey Therapeutics Revenue
In the year 2025, Odyssey Therapeutics had annual revenue of $2.98M, down -33.45%.
Revenue (ttm)
$2.98M
Revenue Growth
-33.45%
P/S Ratio
n/a
Revenue / Employee
$19,709
Employees
151
Market Cap
n/a
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.98M | -1.50M | -33.45% |
| Dec 31, 2024 | 4.47M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionODTX News
- 7 weeks ago - Odyssey Therapeutics Appoints H. Martin Seidel, Ph.D. - Business Wire
- 3 months ago - Odyssey Therapeutics Appoints Jolie M. Siegel as Executive Vice President, General Counsel - Business Wire
- 6 months ago - Odyssey Therapeutics Appoints Dennis Dean, Ph.D., as Executive Vice President, Head of Non-Clinical Development - Business Wire
- 7 months ago - Odyssey Therapeutics Appoints Pharmaceutical Leader Nia Tatsis, Ph.D., to Its Board of Directors - Business Wire
- 8 months ago - Jeito Capital announces significant participation in oversubscribed $213M Series D financing for Odyssey Therapeutics to advance clinical pipeline addressing autoimmune diseases with high unmet needs - GlobeNewsWire
- 8 months ago - Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases - Business Wire
- 1 year ago - Autoimmune biotech Odyssey Therapeutics files for a $100 million IPO - Renaissance Capital
- 1 year ago - Odyssey Therapeutics IPO Registration Document (S-1) - SEC